News | March 16, 2026
C2N Diagnostics expands Alzheimer’s blood test to South Korea via BeauBrain partnership
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
Over 8.8?million Indians aged 60 and above currently live with dementia,
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
The company is excluding data from the affected sites to maintain the study's integrity
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Subscribe To Our Newsletter & Stay Updated
